DB05411ExperimentalProtein Based Therapies
VB2-011 is an antibody developed as an anti-cancer treatment. According to some preclinical studies, it has a potential to inhibit tumour growth in various cancers including lymphoma and melanoma. This... This drug includes the parent IgM (H11 IgM) and a recombinant IgG version (H11 IgG).
- Primary indication
- Investigated for use/treatment in cancer/tumors (unspecified).Curator reviewed
- Code names
- VB2-011
Which companies are running trials of VB2-011, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account